Schrodinger, Inc. (SDGR) Stock
SDGR has an Alpha Score of 36 out of 100 (weak), computed on Nov 4, 2026 from 2 of 4 sub-scores. 2 of the hedge funds AlphaScala tracks reported SDGR in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is ARK Invest's at $35.00M. Company insiders reported 0 open-market buys and 2 sales on SEC Form 4 in the 90 days to Nov 3, 2026.
What is SDGR's Alpha Score?
How it works →Alpha Score of 36 reflects weak overall profile with moderate momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 4, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own SDGR?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| ARK Invest Cathie Wood | 2.15M | $35.00M | +4% |
| Citadel Ken Griffin | 896K | $14.56M | +354% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Schrodinger, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 17, 26 | Akinsanya Karen | See Remarks | SELL | 10.0K | $280K |
| Sep 17, 26 | Akinsanya Karen | See Remarks | SELL | 21.6K | $648K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →What are SDGR's key statistics?
Key statistics as of Nov 4, 2026
How does SDGR's valuation compare with the Healthcare sector?
| Metric | SDGR | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -20.98% | 4.64% | 150 |
| Return on equity | -16.37% | 6.41% | 169 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 4, 2026). P/E excludes loss-making companies.
SDGR price chart
Powered by TradingViewWhat does Schrodinger, Inc. do?
Schrödinger, Inc. develops a physics-based computational platform that enables the discovery of novel molecules for drug development and materials applications. The company operates in two primary segments: Software and Drug Discovery. The Software segment provides advanced computational tools to biopharmaceutical and biotechnology companies, as well as materials science firms, transforming molecular discovery processes in life sciences and related industries. The Drug Discovery segment builds a portfolio of preclinical and clinical programs, advancing proprietary candidates like the MALT1 inhibitor SGR-1505 and pursuing collaborations with partners such as Novartis, Lilly, Ajax Therapeutics, and Copernic Catalysts to target specific therapeutic areas including oncology and rare diseases. Founded in 1990 and headquartered in New York, Schrödinger, Inc. plays a pivotal role in accelerating innovation at the intersection of computational chemistry, AI-driven simulations, and drug design, supporting research from target identification through clinical validation.